These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21515323)

  • 1. GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.
    Li Y; Zheng X; Tang L; Xu W; Gong M
    Peptides; 2011 Jun; 32(6):1303-12. PubMed ID: 21515323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo.
    Li Y; Xu W; Tang L; Gong M; Zhang J
    Peptides; 2011 Jul; 32(7):1408-14. PubMed ID: 21664938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1.
    Li Y; Li X; Zheng X; Tang L; Xu W; Gong M
    Peptides; 2011 Jul; 32(7):1400-7. PubMed ID: 21600946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo.
    Cao Z; Li Y; Tang L; Xu W; Liu C; Zhang J; Gong M
    Diabetes Res Clin Pract; 2012 Jun; 96(3):362-70. PubMed ID: 22284602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes.
    Zheng X; Li Y; Li X; Tang L; Xu W; Gong M
    Diabetes Res Clin Pract; 2011 Sep; 93(3):410-20. PubMed ID: 21641071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
    Lecube A; Bueno M; Suárez X
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
    Irwin N; Patterson S; de Kort M; Moffett RC; Wisse JA; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    ChemMedChem; 2015 Aug; 10(8):1424-34. PubMed ID: 26059252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
    Egan JM; Meneilly GS; Elahi D
    Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1072-9. PubMed ID: 12475750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
    Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.
    Holst JJ
    Diabetologia; 2006 Feb; 49(2):253-60. PubMed ID: 16416146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
    Holst JJ; Seino Y
    Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.
    Liu WJ; Jin HY; Lee KA; Xie SH; Baek HS; Park TS
    Br J Pharmacol; 2011 Nov; 164(5):1410-20. PubMed ID: 21323903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.